Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20732205 | 0.86 | KDM4E (0.50) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL28563393 | 0.82 | TLR8 (0.32) | ALDH1A1MAPTHPGDKDM4EIKBKB | |
| SCHEMBL20722528 | 0.81 | KDM4E (0.54) | ALDH1A1MAPTKDM4EHTTSMN1; SMN2 | |
| SCHEMBL28563392 | 0.78 | LMNA (0.40) | PKMALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL23938072 | 0.72 | HSD17B10 (0.47) | MAPTLIMK1SMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL20731142 | 0.72 | GAA (0.38) | MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL168802 | 0.71 | ALDH1A1 (0.44) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL23938071 | 0.69 | HSD17B10 (0.35) | MAPTALOX15HSD17B10 | |
| SCHEMBL21048217 | 0.69 | MAPT (0.50) | PKMALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14955139 | 0.69 | CHRM4 (0.68) | PKMALDH1A1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PKM 3353/4885ALDH1A1 2167/4885MAPT 2661/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | PKM 3353/4885ALDH1A1 2167/4885MAPT 2661/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PKM 3353/4885ALDH1A1 2167/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.